ATE239493T1 - Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen - Google Patents

Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen

Info

Publication number
ATE239493T1
ATE239493T1 AT94927059T AT94927059T ATE239493T1 AT E239493 T1 ATE239493 T1 AT E239493T1 AT 94927059 T AT94927059 T AT 94927059T AT 94927059 T AT94927059 T AT 94927059T AT E239493 T1 ATE239493 T1 AT E239493T1
Authority
AT
Austria
Prior art keywords
hgf
cranial nerve
producing
nervous system
central nervous
Prior art date
Application number
AT94927059T
Other languages
English (en)
Inventor
Toshikazu Nakamura
Original Assignee
Sumitomo Pharma
Toshikazu Nakamura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma, Toshikazu Nakamura filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE239493T1 publication Critical patent/ATE239493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94927059T 1993-09-17 1994-09-16 Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen ATE239493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25485993A JP3680114B2 (ja) 1993-09-17 1993-09-17 脳神経障害治療剤
PCT/JP1994/001533 WO1995007709A1 (en) 1993-09-17 1994-09-16 Remedy for cranial nerve disorder

Publications (1)

Publication Number Publication Date
ATE239493T1 true ATE239493T1 (de) 2003-05-15

Family

ID=17270838

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927059T ATE239493T1 (de) 1993-09-17 1994-09-16 Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen

Country Status (6)

Country Link
US (1) US6699837B2 (de)
EP (1) EP0722737B1 (de)
JP (1) JP3680114B2 (de)
AT (1) ATE239493T1 (de)
DE (1) DE69432638T2 (de)
WO (1) WO1995007709A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032960A1 (fr) * 1995-04-21 1996-10-24 Mitsubishi Chemical Corporation Medicament preventif ou therapeutique, ou les deux, pour les affections ischemiques
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
AU4027601A (en) * 1995-07-11 2001-07-26 Snow Brand Milk Products Co., Ltd. Lyophilized HGF preparations
EP1132098B1 (de) 1999-09-21 2010-05-26 AnGes MG, Inc. Gentherapie für zerebrale gefässerkrankungen
EP1291358A4 (de) * 2000-05-31 2004-07-21 Nippon Zenyaku Kogyo Co Ltd Hepatocyten-wachstumsfaktor aus der katze
EP1320384B1 (de) 2000-08-28 2007-10-10 Damavand Wound AB Die synergistischen wirkungen von hgf und antibakterieller behandlung
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
JP5442173B2 (ja) * 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
AU2002349583B2 (en) * 2001-11-28 2007-11-22 Anges Mg, Inc. Genetic remedies for neurodegenerative diseases
EP1532987A4 (de) * 2002-06-06 2005-12-28 Anges Mg Inc Mittel für die gentherapie bei zerebrovaskulären erkrankungen
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
WO2005001080A2 (en) 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
CA2541603A1 (en) * 2003-10-14 2005-04-21 Kringle Pharma Inc. Agent for improving mental disorders
JP4716875B2 (ja) 2003-12-16 2011-07-06 敏一 中村 糖鎖欠損型肝細胞増殖因子
US20080025962A1 (en) * 2004-11-30 2008-01-31 Angesmg,Inc. Remedy for Alzheimer's Disease
US7696170B2 (en) 2005-01-24 2010-04-13 Kringle Pharma Inc. Fibrosis inhibitor for implanted organ
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
US8575099B2 (en) * 2006-04-20 2013-11-05 Osaka University Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
JP5093783B2 (ja) 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
WO2008102452A1 (ja) * 2007-02-22 2008-08-28 Kringle Pharma Inc. Ｈｇｆ製剤
JP5580598B2 (ja) 2007-11-15 2014-08-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 γ−セクレターゼの新規基質ＥｐｈＡ７を利用したスクリーニング方法
CN102149379A (zh) 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
US8927493B2 (en) * 2008-10-10 2015-01-06 Kringle Pharma, Inc. Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
BRPI0923177A2 (pt) * 2008-12-19 2020-08-25 Advanced Technologies And Regenerative Medicine, Llc usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit
CN102387807A (zh) 2008-12-19 2012-03-21 先进科技及再生医学有限责任公司 肺部疾病和病症的治疗
JP6095893B2 (ja) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド 傷害後の神経組織の再生および修復
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
JP6059017B2 (ja) 2010-12-17 2017-01-11 エーザイ・アール・アンド・ディー・マネジメント株式会社 ゼラチナーゼによるＥｐｈＡ４の切断反応を指標としたスクリーニング方法
JP5961608B2 (ja) 2011-04-25 2016-08-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 ＥｐｈＡ４細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法
KR101446711B1 (ko) * 2011-05-23 2014-10-06 아주대학교산학협력단 간세포 성장인자 유전자 및 염기성 나선-고리-나선 계열의 신경형성 전사인자 유전자가 도입된 성체 줄기세포주 및 그의 용도
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
WO2016039163A1 (ja) * 2014-09-10 2016-03-17 クリングルファーマ株式会社 神経疾患の治療に適したｈｇｆ製剤
CN109477119A (zh) * 2016-02-04 2019-03-15 斯比根公司 表达肝细胞生长因子的间充质干细胞及其用途
KR102275262B1 (ko) * 2016-03-17 2021-07-12 에자이 알앤드디 매니지먼트 가부시키가이샤 활성 간세포 성장 인자(hgf)를 생성하는 방법
EP3927702A4 (de) 2019-04-11 2022-05-11 Angion Biomedica Corp. Feste formen von (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazol
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
US20220133687A1 (en) * 2020-11-02 2022-05-05 Synaptogenix, Inc. Methods of treating and preventing neurodegenerative diseases with hgf activating compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0484416A1 (de) * 1989-07-27 1992-05-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Regelung der synthese des nervenwachstumsfaktors im zentralen nervensystem
JP2784455B2 (ja) * 1990-05-09 1998-08-06 敏一 中村 肝硬変治療剤
JP2750372B2 (ja) * 1990-06-19 1998-05-13 敏一 中村 賢疾患治療剤
US5227158A (en) * 1991-06-10 1993-07-13 Genentech, Inc. Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon
JPH05213733A (ja) * 1992-02-05 1993-08-24 Sansho Seiyaku Co Ltd 皮膚化粧料
KR100271087B1 (en) * 1992-07-16 2000-11-01 Snow Brand Milk Products Co Ltd Protein synthesis stimulator comprising tcf-2 for the treatment of hypoproteinemia
CA2144081C (en) * 1992-09-16 2004-11-30 Filip Roos Protection against liver damage by hgf

Also Published As

Publication number Publication date
JP3680114B2 (ja) 2005-08-10
EP0722737A4 (de) 1999-04-28
EP0722737A1 (de) 1996-07-24
EP0722737B1 (de) 2003-05-07
DE69432638T2 (de) 2004-02-26
DE69432638D1 (de) 2003-06-12
US20030060403A1 (en) 2003-03-27
JPH0789869A (ja) 1995-04-04
US6699837B2 (en) 2004-03-02
WO1995007709A1 (en) 1995-03-23

Similar Documents

Publication Publication Date Title
ATE239493T1 (de) Anwendung von hgf zur herstellung eines medikaments gegen zentralnervensystemstörungen
DK0812190T3 (da) R-enantiomer af N-propargyl-1-aminoindan til behandling af forskellige sygdomme og mesylat, esulat og sulfat deraf
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
HU9203383D0 (en) 2-amino-methyl-chromane derivatives and method for producing said compounds and pharmaceutical preparatives containing them
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE60140054D1 (de) Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
WO2006041871A3 (en) Apparatus and method for modulating neurochemical levels in the brain
DE60018554D1 (de) Arzneimittel zur förderung der neuronalen zelldifferenzierung, die cyclische glycerophosphate und deren analoga enthalten
Martineau et al. Evoked potentials and P300 during sensory conditioning in autistic children.
DE69431199D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
AU653802B2 (en) Condensed diazepinones
ATE142643T1 (de) Wachstumsinhibierender faktor und für den wachstumsinhibierenden faktor kodierender cdns
EP0495998A4 (de)
ATE263573T1 (de) Die verwendung von wachstumshormon zur herstellung eines medikaments zur behandlung der ischämischen hirnschädigung und demenz
ATE236652T1 (de) Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
DE60008111D1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties